Boston, MA & Tokyo, Japan – April 17, 2026 – In a significant move to enhance the precision and efficacy…
Read More
The Dawn of In Vivo Cell Therapies: A New Era in Precision Medicine Unfolds Amidst Significant Investment and Innovation
The pharmaceutical landscape is witnessing a profound transformation with the ascendance of in vivo cell therapies, a revolutionary approach that…
Read More
Aligos Therapeutics Licenses Pevifoscorvir Sodium to Xiamen Amoytop Biotech for Greater China, Bolstering HBV Treatment Landscape
Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech, granting the Chinese biopharmaceutical company the rights…
Read More
Eli Lilly is now pharma’s top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn’t celebrating
In a landmark announcement on April 1, the U.S. Food and Drug Administration (FDA) granted approval to Foundayo (orforglipron), Eli…
Read More
Kailera Therapeutics Secures $625 Million in Landmark IPO to Accelerate Obesity Drug Development
Obesity-focused biotechnology firm Kailera Therapeutics has successfully launched its Initial Public Offering (IPO), raising an impressive $625 million. This significant…
Read More
Nucleai and Sirona Dx Forge Strategic Alliance to Revolutionize Spatial Proteomics for Drug Development
The pharmaceutical and biotechnology sectors are poised for a significant leap forward in drug development with the formation of a…
Read More
Eli Lilly Faces Regulatory Scrutiny Over Foundayo’s Long-Term Safety Profile
Eli Lilly has swiftly responded to concerns raised by the US Food and Drug Administration (FDA) regarding the long-term safety…
Read More
Paradigm Health Unveils AI-Powered Platform Revolutionizing Clinical Trial Execution
Paradigm Health is redefining the landscape of clinical research with its innovative, AI-powered platform designed to streamline the entire trial…
Read More
Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases
Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…
Read More
Johnson & Johnson Forecasts Accelerated Growth in 2026 Driven by New Psoriasis Treatment, Icotyde, and Robust Pharma Portfolio
Johnson & Johnson (J&J) has reported a strong start to 2026, exceeding analyst expectations with robust first-quarter earnings and revising…
Read More
